Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03272633 · ClinicalTrials.gov registry record · Early Phase 1
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT03272633 is a Early Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 2 participants.
The verdict
NCT03272633, a Early Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.
Interventions
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
- BIOLOGICAL Irradiated Allogeneic Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2022-09-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03272633
The ClinicalTrials.gov registry entry for NCT03272633 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allogeneic Hematopoietic Stem Cell Transplantation is the first listed.
NCT03272633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03272633 about?
NCT03272633 is a clinical study titled "Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies". This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may ...
What is the current status of trial NCT03272633?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2020-10-26. Estimated completion is 2022-09-22.
What interventions are being tested in trial NCT03272633?
The interventions under investigation include: Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE), Irradiated Allogeneic Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03272633?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.